Allan R. Glanville
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Allan R. Glanville has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
- Alicia B. Mitchell
Sydney Medical School, University of Sydney, Sydney, Australia
5 shared publications - Ayodeji Adegunsoye
Department of Medicine, Section of Pulmonary & Critical Care, University of Chicago , Chicago, IL
2 shared publications Christian Benden
Division of Pulmonary Medicine, University Hospital Zürich, Zürich, Switzerland
2 shared publications- Christian Benden
University of Zurich, Switzerland; Boston Children's Hospital and Harvard Medical School, Boston, Massachusetts
2 shared publications Christina Aboyoun
The Lung Transplant Unit, St. Vincent's Hospital, Sydney, New South Wales, Australia
2 shared publications- Daniel Charles Chambers
School of Medicine The University of Queensland Brisbane Queensland Australia
2 shared publications
Latest Publications
- 1 April 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (4) , 560-568
Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease
- 1 April 2025
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 211 (4) , 560-568
Impact of Environmental Exposures on the Development and Progression of Fibrotic Interstitial Lung Disease
- Open Access
- 15 October 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (8) , 1065-1066
The Emperor’s New Clothes Revisited
- 15 October 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (8) , 1065-1066
Open AccessThe Emperor’s New Clothes Revisited
- Top Cited PapersOpen Access
- 15 August 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (4) , 401-423
Genetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine
Recent genetic and genomic advancements have elucidated the complex etiology of idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases (ILDs), emphasizing the contribution of heritable factors. This state-of-the-art review synthesizes evidence on significant genetic contributors to pulmonary fibrosis (PF), including rare genetic variants and common SNPs. The MUC5B promoter variant is unusual, a common SNP that markedly elevates the risk of early and established PF. We address the utility of genetic variation in enhancing understanding of disease pathogenesis and clinical phenotypes, improving disease definitions, and informing prognosis and treatment response. Critical research gaps are highlighted, particularly the underrepresentation of non-European ancestries in PF genetic studies and the exploration of PF phenotypes beyond usual interstitial pneumonia/IPF. We discuss the role of telomere length, often critically short in PF, and its link to progression and mortality, underscoring the genetic complexity involving telomere biology genes (TERT, TERC) and others like SFTPC and MUC5B. In addition, we address the potential of gene-by-environment interactions to modulate disease manifestation, advocating for precision medicine in PF. Insights from gene expression profiling studies and multiomic analyses highlight the promise for understanding disease pathogenesis and offer new approaches to clinical care, therapeutic drug development, and biomarker discovery. Finally, we discuss the ethical, legal, and social implications of genomic research and therapies in PF, stressing the need for sound practices and informed clinical genetic discussions. Looking forward, we advocate for comprehensive genetic testing panels and polygenic risk scores to improve the management of PF and related ILDs across diverse populations.
- 15 August 2024
- Published by Oxford University Press (OUP) in American Journal of Respiratory and Critical Care Medicine
- Vol. 210 (4) , 401-423
Top Cited PapersOpen AccessGenetics and Genomics of Pulmonary Fibrosis: Charting the Molecular Landscape and Shaping Precision Medicine
Recent genetic and genomic advancements have elucidated the complex etiology of idiopathic pulmonary fibrosis (IPF) and other progressive fibrotic interstitial lung diseases (ILDs), emphasizing the contribution of heritable factors. This state-of-the-art review synthesizes evidence on significant genetic contributors to pulmonary fibrosis (PF), including rare genetic variants and common SNPs. The MUC5B promoter variant is unusual, a common SNP that markedly elevates the risk of early and established PF. We address the utility of genetic variation in enhancing understanding of disease pathogenesis and clinical phenotypes, improving disease definitions, and informing prognosis and treatment response. Critical research gaps are highlighted, particularly the underrepresentation of non-European ancestries in PF genetic studies and the exploration of PF phenotypes beyond usual interstitial pneumonia/IPF. We discuss the role of telomere length, often critically short in PF, and its link to progression and mortality, underscoring the genetic complexity involving telomere biology genes (TERT, TERC) and others like SFTPC and MUC5B. In addition, we address the potential of gene-by-environment interactions to modulate disease manifestation, advocating for precision medicine in PF. Insights from gene expression profiling studies and multiomic analyses highlight the promise for understanding disease pathogenesis and offer new approaches to clinical care, therapeutic drug development, and biomarker discovery. Finally, we discuss the ethical, legal, and social implications of genomic research and therapies in PF, stressing the need for sound practices and informed clinical genetic discussions. Looking forward, we advocate for comprehensive genetic testing panels and polygenic risk scores to improve the management of PF and related ILDs across diverse populations.
- 30 May 2024
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 30 (4) , 375-376
Lung transplantation: practical and important directions of care
- 30 May 2024
- Published by Wolters Kluwer Health in Current Opinion in Pulmonary Medicine
- Vol. 30 (4) , 375-376
Lung transplantation: practical and important directions of care
- 9 February 2023
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 44 (1) , 137-157
Acute Rejection and Chronic Lung Allograft Dysfunction
- 9 February 2023
- Published by Elsevier in Clinics in Chest Medicine
- Vol. 44 (1) , 137-157
Acute Rejection and Chronic Lung Allograft Dysfunction
- Open Access
- 7 February 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (7) , 908-916
A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant
- 7 February 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 42 (7) , 908-916
Open AccessA randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant
- Open Access
- 25 July 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (3)
Bronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions
Bronchiolitis obliterans syndrome (BOS) may develop after either lung or haematopoietic stem cell transplantation (HSCT), with similarities in histopathological features and clinical manifestations. However, there are differences in the contributory factors and clinical trajectories between the two conditions. BOS after HSCT occurs due to systemic graft-versus-host disease (GVHD), whereas BOS after lung transplantation is limited to the lung allograft. BOS diagnosis after HSCT is more challenging, as the lung function decline may occur due to extrapulmonary GVHD, causing sclerosis or inflammation in the fascia or muscles of the respiratory girdle. Treatment is generally empirical with no established effective therapies. This review provides rare insights and commonalities of both conditions, which are not well elaborated elsewhere in contemporary literature, and highlights the importance of cross disciplinary learning from experts in other transplant modalities. Treatment algorithms for each condition are presented, based on the published literature and consensus clinical opinion. Immunosuppression should be optimised, and other conditions or contributory factors treated where possible. When initial treatment fails, the ultimate therapeutic option is lung transplantation (or re-transplantation in the case of BOS after lung transplantation) in carefully selected candidates. Novel therapies under investigation include aerosolised liposomal cyclosporine, Janus kinase inhibitors, antifibrotic therapies and (in patients with BOS after lung transplantation) B-cell-directed therapies. Effective novel treatments that have a tangible impact on survival and thereby avoid the need for lung transplantation or re-transplantation are urgently required.
- 25 July 2022
- Published by European Respiratory Society (ERS) in ERJ Open Research
- Vol. 8 (3)
Open AccessBronchiolitis obliterans syndrome after lung or haematopoietic stem cell transplantation: current management and future directions
Bronchiolitis obliterans syndrome (BOS) may develop after either lung or haematopoietic stem cell transplantation (HSCT), with similarities in histopathological features and clinical manifestations. However, there are differences in the contributory factors and clinical trajectories between the two conditions. BOS after HSCT occurs due to systemic graft-versus-host disease (GVHD), whereas BOS after lung transplantation is limited to the lung allograft. BOS diagnosis after HSCT is more challenging, as the lung function decline may occur due to extrapulmonary GVHD, causing sclerosis or inflammation in the fascia or muscles of the respiratory girdle. Treatment is generally empirical with no established effective therapies. This review provides rare insights and commonalities of both conditions, which are not well elaborated elsewhere in contemporary literature, and highlights the importance of cross disciplinary learning from experts in other transplant modalities. Treatment algorithms for each condition are presented, based on the published literature and consensus clinical opinion. Immunosuppression should be optimised, and other conditions or contributory factors treated where possible. When initial treatment fails, the ultimate therapeutic option is lung transplantation (or re-transplantation in the case of BOS after lung transplantation) in carefully selected candidates. Novel therapies under investigation include aerosolised liposomal cyclosporine, Janus kinase inhibitors, antifibrotic therapies and (in patients with BOS after lung transplantation) B-cell-directed therapies. Effective novel treatments that have a tangible impact on survival and thereby avoid the need for lung transplantation or re-transplantation are urgently required.
- 1 June 2022
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 27 (3) , 167-168
Editorial: Current opinion in organ transplantation: lung transplantation
- 1 June 2022
- Published by Wolters Kluwer Health in Current Opinion in Organ Transplantation
- Vol. 27 (3) , 167-168
Editorial: Current opinion in organ transplantation: lung transplantation
- 12 February 2021
- Published by Springer Nature
- p. 293-302
PTLD after Lung Transplantation
- 1 October 2020
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 54, 121-129
RNAi therapeutics: an antiviral strategy for human infections
- 1 October 2020
- Published by Elsevier in Current Opinion in Pharmacology
- Vol. 54, 121-129
RNAi therapeutics: an antiviral strategy for human infections